Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | Director · President & CEO | October 18, 2021 | October 20, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date October 18, 2021 · Filed October 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2031-10-18 | Direct | 4,275,000 |
Reported balance
After 2021-10-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-10-18 · Grant · Acquired 4,275,000 · Balance 4,275,000 F1: The options will vest in 3 equal annual installments beginning on August 6, 2022, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in 3 equal annual installments beginning on August 6, 2022, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 18, 2021 Filed Oct 20, 2021 20:13 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 4,275,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0000899243-21-040751 · doc4.xml · derivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,275,000 Underlying: Common Stock · 4,275,000 shares Expires 2031-10-18 F1 · derivative.exercise_date: The options will vest in 3 equal annual installments beginning on August 6, 2022, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:49 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032402 · doc4.xml · nonDerivative · entry 2 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,850,688 F2 · shares: Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors. F2 · price: Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:49 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon stock | 75,758 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-032402 · doc4.xml · nonDerivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650,688 F1 · shares: Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. F1 · price: Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:08 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified Stock Option · Derivative | 2,000,000 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0001807094-20-000017 · primary_doc.xml · derivative · entry 2 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2030-06-15 F3 · date: The option grant was approved by a committee of the Issuer's Board of Directors on June 15, 2020, subject to stockholder approval of the Issuer's Amended & Restated 2012 Equity Incentive Plan (the "Plan") under which the option was granted. The Issuer's stockholders approved the Plan on September 30, 2020. F4 · derivative.exercise_date: The stock option vests annually in three equal installments beginning June 15, 2021. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:08 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001807094-20-000017 · primary_doc.xml · nonDerivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,574,930 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Amended & Restated 2012 Equity Incentive Plan. F2 · price: Not applicable. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 00:59 UTC | CytoDyn Inc. CYDY · Entity 5856 | Tax withholdingCommon Stock | 156,570 | $4.97 | $778,152.90 |
DisclosureSEC source: 0001807094-20-000014 · primary_doc.xml · nonDerivative · entry 2 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,074,930 Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 00:59 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 323,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001807094-20-000014 · primary_doc.xml · nonDerivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,500 Read SEC document |
| May 04, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 30,933 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 27 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,250 Underlying: Common Stock · 30,933 shares Expires 2029-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · balance_after: Option grant vests in equal monthly installments over a 12-month period beginning October 7, 2019. Read SEC document |
| May 04, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 1,201,652 | $2.79 | $3,353,089.74 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 14 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908,343 F3 · price: This transaction was executed in multiple trades at prices ranging from $2.53 to $3.00. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 04, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 30,933 | $0.39 | $12,063.87 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 13 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,109,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 1,399,685 | $3.26 | $4,569,131.71 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 12 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,079,062 F2 · price: This transaction was executed in multiple trades at prices ranging from $3.13 to $3.54. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 2,000,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 26 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000,000 shares Expires 2029-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 187,817 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 25 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,183 Underlying: Common Stock · 187,817 shares Expires 2029-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · balance_after: Option grant vests in equal monthly installments over a 12-month period beginning October 7, 2019. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 1,000,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 24 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2028-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 116,550 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 23 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,450 Underlying: Common Stock · 116,550 shares Expires 2028-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · balance_after: Option grant vests over a three year period beginning June 8, 2019. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 600,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 22 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 50,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 21 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 199,800 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 20 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,200 Underlying: Common Stock · 199,800 shares Expires 2027-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Option grant vests over a three year period beginning June 1, 2018. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 600,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 19 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2026-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 152,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 18 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,000 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 325,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 17 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 325,000 shares Expires 2025-11-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionEmployee Stock Option · Derivative | 150,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · derivative · entry 16 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | SaleCommon Stock | 2,219,837 | $3.53 | $7,838,688.41 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 11 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,478,747 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.44 to $3.74. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 2,000,000 | $0.63 | $1,260,000.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 10 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,698,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 187,817 | $0.39 | $73,248.63 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 9 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,698,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 1,000,000 | $0.57 | $565,000.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 8 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,510,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 116,550 | $0.49 | $57,109.50 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 7 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,510,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 600,000 | $0.80 | $480,000.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 6 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,394,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 199,800 | $0.57 | $113,886.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 5 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 600,000 | $1.09 | $654,000.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 4 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,594,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 152,000 | $0.75 | $114,000.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 3 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 994,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 325,000 | $0.87 | $282,750.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 2 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2020 Filed May 5, 2020 01:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | Exercise / conversionCommon Stock | 200,000 | $0.90 | $180,000.00 |
DisclosureSEC source: 0001807094-20-000005 · primary_doc.xml · nonDerivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 517,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 24, 2019 Filed Dec 28, 2019 01:05 UTC | CytoDyn Inc. CYDY · Entity 5856 | Tax withholdingCommon Stock | 70,055 | $0.64 | $44,835.20 |
DisclosureSEC source: 0000899243-19-030134 · doc4.xml · nonDerivative · entry 2 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,417 Read SEC document |
| December 24, 2019 Filed Dec 28, 2019 01:05 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 225,983 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-030134 · doc4.xml · nonDerivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,472 F1 · price: The reported securities were granted in respect of an annual performance award for the fiscal year ended May 31, 2018, which had been previously approved but not yet issued. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:17 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantWarrant (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030010 · doc4.xml · derivative · entry 2 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: The warrant vests upon the achievement of certain additional strategic milestones. Read SEC document |
| December 19, 2019 Filed Dec 24, 2019 00:17 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0000899243-19-030010 · doc4.xml · derivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2029-12-19 Read SEC document |
| October 07, 2019 Filed Oct 8, 2019 23:05 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 375,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-19-025316 · doc4.xml · derivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2029-10-07 F1 · derivative.exercise_date: The options will vest in twelve equal monthly installments over the one year period commencing on November 7, 2019. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 00:57 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000899243-19-017503 · doc4.xml · derivative · entry 1 Pourhassan Nader · CIK 0001532878 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-18 Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 1,000,000 | Not disclosed Strike: $0.57 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 13 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2028-11-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F7 · derivative.exercise_date: 50% of the options were fully vested and exercisable as of their issuance date, and 50% of the options vest on April 8, 2019. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 350,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 12 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350,000 shares Expires 2028-06-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F6 · derivative.exercise_date: The options vest in three equal annual installments commencing on June 1, 2019. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 600,000 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 11 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2023-02-15 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 300,000 | Not disclosed Strike: $0.57 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 10 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2027-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F5 · derivative.exercise_date: The options vest in three equal annual installments commencing on June 1, 2018. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 600,000 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 9 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2026-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F4 · derivative.exercise_date: The options vest in three equal annual installments commencing on June 1, 2017. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 304,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 8 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 304,000 shares Expires 2026-01-04 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · derivative.exercise_date: The options vest upon the achievement of certain strategic milestones specified in the award agreement. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 650,000 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 7 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 650,000 shares Expires 2025-11-23 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · derivative.exercise_date: The options vest upon the achievement of certain strategic milestones specified in the award agreement. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 200,000 | Not disclosed Strike: $0.90 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 6 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2025-06-30 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 54,545 | Not disclosed Strike: $2.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 5 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54,545 shares Expires 2022-03-23 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 500,000 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 4 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2021-07-31 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:25 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 200,000 | Not disclosed Strike: $0.64 | Not disclosed |
DisclosureSEC source: 0000899243-18-029184 · doc4.xml · derivative · entry 3 Pourhassan Nader · CIK 0001532878 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2019-05-29 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.